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Abstract
MOLECULAR BASIS OF CROSS-SENSITIZATION IN COLONIC INFLAMMATIONINDUCED SOMATIC HYPERSENSITIVITY

By: Parshva Mehta
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Physiology and Biophysics at Virginia Commonwealth University
Virginia Commonwealth University, 2021
Professor: Dr. Liya Qiao, PhD
VCU School of Medicine
Physiology and Biophysics

A major portion of pain experienced by patients with an Irritable Bowel Disease (IBD) or
Irritable Bowel Syndrome (IBS) can be attributed to visceral hypersensitivity. Visceral stimuli
transmitted through primary afferent neurons in the dorsal root ganglia (DRG) induce a
nociceptive response. Notably, a subset of patients have also experienced the development of
somatic pain, such as leg pain, after diagnosis of a bowel disorder. The aim of this investigation
is to ascertain which biochemical mediators are involved in the development of such
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viscerosomatic cross-sensitization. Initially, the Von Frey Test was used to find behavioral
evidence of somatic referred pain; TNBS-induced mice exhibited a greater withdrawal response
to hindpaw stimulation than control mice. Then, fast blue retrograde tracing was conducted and
hindpaw innervation was identified to occur via primary afferent neurons located in the DRG at
L4 spinal level. Immunohistochemical studies were conducted on L4 DRG tissue to evaluate
levels of cellular mediators known to be involved in pain signaling, such as phosphor(p)-Akt. L4
DRG from TNBS-treated mice exhibited significantly higher levels of phospho-Akt
than control animals. The increased p-Akt was located in Piezo2-expressing L4 DRG neurons
and was suppressed in mice lacking TrkB.T1. These findings suggest that the PI3K/Akt pathway
regulated by TrkB.T1-mediated cellular events participates in viscerosomatic cross-organ
sensitization.
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Introduction
1.1 Inflammatory Bowel Disease
Inflammatory Bowel Diseases are characterized by inflammation and disruption within
the gastrointestinal tract. The prevalence of IBD in North America and Europe has been a
significant problem and it continues to grow due to a young age of onset and low mortality (1).
Cases are rapidly increasing in newly industrialized countries around the world, particularly in
Asia, Africa, and South America. Studies reveal that there is no significant difference in IBD
cases amongst men and women, and there also does not seem to be significant variation by race
(2). Early onset of this disease is fairly common; previous findings by McDowell et al. estimate
that up to a fourth of patients may develop IBD by adolescence. A 2019 study approximated that
2 million people have been affected by IBD in North America, and that this number is projected
to double by 2030 (3). In terms of financial cost, this disease was expected to cost the healthcare
systems of the United States and Canada around 10 billion US dollars as of 2018 (3). Given the
increasing prevalence around the world and the projected population affected, this disease can
become a significant global burden. When considering the future, the early onset of IBD may
also present complex cases/comorbidities due to longer disease duration (1).
IBDs can be differentiated into two types: Crohn’s Disease (CD) or Ulcerative Colitis (UC);
if either of these cannot be confidently diagnosed, then the condition is considered IBDundifferentiated (IBD-U) (4). Common symptoms of IBDs in affected patients include diarrhea,
abdominal pain, weight loss, and/or bloody stools (5).
Crohn’s Disease (CD) can involve any aspect of the gastrointestinal tract ranging from the
mouth to the anus. Most commonly, CD affects the ileum and/or the large intestine, generally in
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a discontinuous pattern. The symptoms vary based on the location and severity of disease,
resulting in varying clinical presentation from one patient to another. Common symptoms
include abdominal pain, watery diarrhea, and weight loss. This pain is acute and severe,
generally localizing to the right lower quadrant (5). The abdominal pain and the diarrhea tend to
be episodic and can occur intermittently for years prior to diagnosis. A key feature of Crohn’s is
that it affects all layers of the bowel (1), potentially leading to strictures or fistulas. CD can cause
serious problems for the skin and also lead to biliary stones over time (2). Systemic symptoms
can also be seen due to CD, with fatigue being the most common (due to persistent inflammation
and malabsorption) (5).
Ulcerative Colitis (UC) generally involves inflammation confined to the colon, and
therefore symptoms are not as diverse as those in CD (4, 8). The inflammation tends to start in
the rectum and spreads in a continuous pattern towards the proximal colon. While the large
intestine gets inflamed, the small intestine continues to function normally (7). In contrast with
CD, UC only affects the innermost layer of the colon or other affected areas. UC frequently
presents as bloody diarrhea, and patients often describe tenesmus, a sensation of incomplete
emptying. The extent of blood present in the stool can be indicative of the severity of disease (8).
Physical exams often reveal left lower or upper quadrant abdominal pain. If UC lasts for 8-10
years, it can lead to osteoporosis or even colon cancer. With longer disease courses, patients may
also develop colonic strictures which cause obstruction/pain (8).
The cause of IBDs continues to be a mystery; various factors seem to be involved, but
there has not been a universal aspect which is consistent among all patients. Genetic and
environmental factors are certainly involved, and patients with compromised or inappropriate
immune responses are particularly susceptible (6, 7). Recent Genome wide association studies

3

(GWAS) have revealed 240 nonoverlapping genetic loci, of which 30 are common to both UC
and CD. Analysis of these loci indicate their role in important pathways for intestinal
homeostasis (5). Environmentally, the intestinal microbiota is the major driver of IBD; the gut
bacteria affect the immune system, host metabolism, and GI development in major ways.
The goal of treatment is to induce remission of IBD, and it varies based on the severity of the
disease. Nonbiological therapies such as aminosalicylates, thiopurines, and steroids provide
symptomatic relief but do not change the long-term course of disease progression. Biological
therapies involving immunomodulators, such as tumor necrosis factor-a (TNF-a) antibodies,
have induced or maintained remission in certain patients, but a significant portion of IBD
patients were or became non-responders to this treatment; new methods of treatment targeting
specific pathways have become increasingly necessary (9).

1.2 Visceral Hypersensitivity
While the inflammation in IBD is considered to be more severe than that in IBS, a recent
study noted that there can be a significant amount of overlap in symptoms; up to 40% of IBS
symptoms were present in patients with IBS and IBD (10). One of the primary symptoms,
abdominal pain, is present in a plethora of gastrointestinal disorders. This pain may be due to
visceral hypersensitivity; visceral hypersensitivity is defined as enhanced perception of
mechanical triggers applied to the bowels (14). Such improper signaling of the viscera through a
signaling reflex pathway is known to occur in both IBD and IBS, and may be affecting up to
20% of the global population (11). There are two types of hypersensitivity: hyperalgesia and
allodynia. Hyperalgesia is when there is an intensified pain sensation in response to stimuli
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which usually provoke pain. Allodynia is when there is nociceptive sensation in response to
normal stimuli (12).
The sensory pathway through which visceral hypersensitivity occurs is known as the
“gut-brain axis,” with signals going from the periphery to the central nervous system (13).
Perceivable sensations, such as pain, in the colon and rectum are generated by extrinsic afferent
neurons (13, 15). The conscious perception of pain/discomfort in the viscera occurs is signaled to
the brain via these neurons, which respond to noxious mechanical stimuli. These neurons can be
subdivided by the location of soma; splanchnic nerve cell bodies are located within the
thoracolumbar dorsal root ganglion (DRG), and pelvic nerve cell bodies are within the
lumbosacral DRG. DRGs are groups of cells bodies
located all along the human body and convey sensory
information from the Peripheral Nervous System (PNS) to
the Central Nervous System (CNS). Each DRG is
composed of a cluster of pseudounipolar neurons whose
axons project onto the spinal cord transmitting the sensory
signal towards the brain (16). In particular, these neurons
Figure 1: Visceral Organ Sensation. Visceral
organs are innervated by pseudounipolar neurons, or
primary afferent neurons, which transmit onto
second order neurons in the spinal cord. These
second order neurons then convey sensory
information to the brain.

are known to control our sensation of pain and
temperature; for this reason, they have immense potential
as targets in the treatment of chronic pain. Colonic

innervation occurs primarily through the thoracolumbar spinal cord with the signal relaying
through the splanchnic nerves. Rectal innervation is mainly thought to transmit signals through
the lumbosacral spinal cord via the pelvic nerves. Peripheral portions of the afferents in the DRG
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innervating the colorectum then terminate onto second order neurons in the dorsal horns of
vertebrae in the spinal cord which transmit the signal to the brain (13, 17).
In the mouse colon, eight different types of afferent fibers have been identified and five
of these have also been recorded in humans: mucosal afferents, muscular afferents,
muscular/mucosal afferents, vascular endings, and silent afferents (13, 18). Mucosal afferents
have low thresholds for activation, responding mainly to distortion of the colonic mucosal
epithelium. Muscular afferents have low distention thresholds in response to the colorectum, and
likely contribute to nociception when there is high stimulus intensity. Muscular/mucosal
afferents respond to mucosal distortion and circular stretch and aren’t found in splanchnic
innervation of the distal colon. Vascular endings wrap around blood vessels in the mesentery and
submucosa and have the greatest similarity to cutaneous nociceptors. These afferents respond to
high-threshold stimuli, inflammatory/immune mediators, and also noxious distention. The last
group of afferents discussed are mechanically insensitive or “silent” in normal conditions. Three
different types of silent afferents have been identified: those that respond to chemical stimuli
(inflammatory markers) and do not develop mechanical sensitivity, those who develop
mechanical but not chemical sensitivity, and finally those stimulated chemically and
mechanically. (18)
Ultimately, both low threshold and high threshold mechanosensitive afferents are
affected during sensitization and contribute to pain/discomfort; this response can be further
amplified by the recruitment of silent afferents capable of developing mechanosensitivity (13).
Inflammation leads to increased signal intensity and frequency, along with lower thresholds of
activation for these afferent neurons. Experiments comparing control and viscerally inflamed
mice showed an increase in mechanosensitive afferents with a near equivalent decrease in silent
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afferents. In mice exposed to conditions of hypersensitivity for 3 consecutive days, the
proportions of mechanosensitive afferents remained higher for weeks after the inflammatory
agent was last administered (19). The exact mechanism by which inflammation induces such
changes in the extrinsic afferent fibers is still controversial; many chemical mediators may play a
role, including but not limited to amines, peptides, cytokines, and neurotrophins.
Many scientists have attempted to better understand the mechanism of sensitization by
inducing visceral pain in animal models. Although it is difficult for models to serve as a true
representation of this condition in humans, previous studies with mice and rats show behavioral
similarity to that of post-infectious IBS patients, who still perceive pain after inflammation has
abated (20, 22). Inflammation is induced in these animals through the use of certain haptens,
substances which cannot induce inflammation on their own, but cause an inflammatory response
once attached to specific proteins. 2,4,6-trinitrobenzene sulfonic acid (TNBS) is a common
hapten which has been shown to cause inflammation, peaking after 4-5 days and persisting
around a month post-injection. Hypersensitivity in the treated persisted for up to 16 weeks after
inflammation has ceased (21).

1.3 Neurotrophin Signaling
Neurotrophins are a group of proteins that are known for their role in embryonic
development of the PNS and CNS (23). These proteins are essential for neuronal survival,
proliferation, and regulation. Outside of their importance during the embryonic stages,
neurotrophins, particularly nerve growth factor (NGF) and brain-derived neurotrophic factor
(BDNF), play an important role in nociceptive signaling as well. Expression of four
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neurotrophins has been identified in mammals: NGF, BDNF, neurotrophin-3 (NT-3), and
neurotrophin-4 (NT-4) (24).
These neurotrophins mediate cellular
processes by binding to two types of receptors,
Trk tyrosine kinase receptors and the p75NTR
receptor (24). The Trk receptors each have high
selectivity for specific neurotrophins; NGF binds
to TrkA, BDNF and NT-4 bind to TrkB, and NT3 binds to TrkC. The p75NTR receptor can bind to
all of the mammalian neurotrophins with low
affinity (24, 25). The locations of both types of
receptors are variable throughout the body and
neurotrophin binding can affect cellular function in

Figure 2: Neurotrophin Signaling Pathways.
Neurotrophin binding to Trk receptors (orange) or
p75NTR receptors (purple) set off signaling cascades
promoting neuronal survival, synaptic plasticity,
and/or cell growth. However, binding of proneurotrophins to p75NTR receptor in the presence of
sortillin (blue) leads to initiation of apoptotic signals.

diverse ways. After binding, the
neurotrophin/receptor complex is internalized by the cell and growth factor receptors maintain
the signal from endosomes (26). Trk receptor signaling is known to promote cell proliferation
through signaling including but not limited to the PI3K/Akt, MEK/MAPK pathways, and PLCg
pathways (25). Meanwhile, the p75NTR receptor is capable of supporting or inhibiting cell
proliferation. In neurons with both Trk and p75NTR receptors, their physical interaction can
increase ligand affinity and delay degradation of the Trk receptor, prolonging the signal (24).
The immature form of the neurotrophins, pro-neurotrophins, are also capable of binding to the
p75NTR receptor when sortilin is present, leading to transmission of an apoptotic signal via the
Jun kinase pathway (27).
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1.4 BDNF and NGF
As previously mentioned, BDNF and NGF play an important role in pain signaling. NGF
has been found to increase activity of primary afferents through various mechanisms, while
BDNF is more involved in central sensitization (25). In adulthood, NGF was originally thought
to be a means of treating peripheral neuropathy due to its neurotrophic effects, but administration
in clinical trials exacerbated the pain (28). Further experimentation supported this, as levels of
NGF mRNA were elevated during inflammatory conditions (29). In regard to visceral pain,
levels of colonic NGF expression in patients with IBS were positively associated with disease
severity and gut barrier dysfunction (30). The augmented pain sensation in response to NGF may
occur through various mechanisms: lower thresholds, increased recruitment, and/or increased
transcription of the nociceptors (25). NGF signaling is also believed to play a role in the
development of mechanosensitivity in silent afferents (31). Additionally, BDNF was found to be
localized primarily in NGF-sensitive neurons expressing TrkA (32,33). BDNF protein is found to
increase in response to nociceptor activity and can rapidly increase when there are high levels of
NGF during inflammation. BDNF can also be released in response to mucosal NMDA receptor
activation, which is known to be involved in visceral hypersensitivity; this increase in BDNF
was found to occur via an Erk dependent pathway.
Ultimately, there are various mechanisms through which neurotrophins can lead to the
sensitization of DRG neurons. In TNBS-induced colitis, increased expression of the TRPV1
receptor was noted in L1 and S1 level DRGs in conjunction with increased NGF expression; this
increased expression also occurred with NGF treatment and was attributed to activation of the
PI3K/Akt pathway (34). CGRP, an important nociceptive marker, also had elevated levels after
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NGF treatment. CGRP is colocalized with TrkB in lumbar and sacral (L1 and S1 DRG), and
increased CGRP expression correlated with BDNF activation (35). When given BDNF
treatment, increased amount and density of CGRP fibers were also noted. Therefore, NGF may
upregulate BDNF expression, which goes on to upregulate CGRP expression. Further analysis
revealed that this upregulation occurs through the PLCg pathway downstream of BDNF-TrkB,
and the Mek/Erk and PI3K/Akt pathways were not involved (25). Another important molecule,
cAMP-responsive element binding (CREB) protein, was also activated in the neurons which
showed upregulation of CGRP. The involvement of this molecule was confirmed by BDNF
antibody treatment, which attenuated the CREB activation (36). Our growing understanding of
these signaling cascades sheds light on the complexity of visceral hypersensitivity, and also on
which molecules may be worthy targets in medicine.

1.5 Cross-Sensitization
Pain from visceral organs tends to be diffuse and poorly localized, and also can be
associated with somatic pain elsewhere. This “referred” pain has been recognized in numerous
conditions affecting different organs. Such cross-sensitization has been seen in patients between
the stomach and heart, esophagus and heart, colon and urinary bladder, and many other organ
pairings (37). Patients with gastrointestinal conditions often concurrently have comorbidities like
bladder disorders, neck pain, foot pain, etc. The inflammation or damage originating in the GI
system from a certain organ led to sensitization elsewhere in response to certain stimuli. One
clinical survey revealed that patients with chronic bladder pain are up to 100 times more likely to
have IBD relative to the general population (38, 39).
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The development of cross-sensitization is not yet fully understood, and further studies
exploring the pathogenesis of cross-sensitization require an animal model which develops similar
symptoms as those in humans. The rodent TNBS-induced colitis model has shown promise, as
rodents in these conditions have shown bladder hypersensitivity and somatic pain in response to
mechanical stimulation (40). Additionally, rodents are known to have similar neuron-cell
interactions to humans in terms of pain sensation. When considering the mechanism by which
cross-sensitization occurs, interactions among primary afferent neurons and non-neuronal cells
are considered as major players (37). One afferent neuron is generally surrounded by two or
three satellite glial cells (SGCs), and colitis
has led to increased coupling between SGCs
around colonic afferents (41). The afferent
neuron may then release cellular mediators
which transmit the signal to SGCs. The
SGCs then may communicate with SGCs
surrounding another afferent neuron via gap
junctions, allowing for transmission of
nociceptive signals among neurons within
Figure 3: Mouse Model of Cross-Sensitization. Colonic
inflammation leads to increased coupling of SGC and
accumulation of macrophages due to nociceptive signaling from
the neuron. This nociceptive signaling can be transmitted to
heterosegmental afferents via microglia-astrocyte networks in the
spinal cord.

DRG that innervate different organs. For
cross-sensitization between organs which are
not innervated by DRG neurons in the same
spinal segment, it can likely be attributed to

communication between DRG through the spinal cord. A recent study showed that TNBSinduced mice developed somatic heterosegmental and homogesegmental hypersensitivity to the
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hindpaw and low back, respectively (42). Colororectal innervation was traced to L6, low-back
innervation was also in L6, and hindpaw innervation was traced to L4. TNBS treatment led to
hypersensitivity to somatic regions innervated by neurons within the same DRG and to those
innervated by a distinct spinal region in L4 (42). The central sensitization likely triggered by the
release of mediators into the spinal cord (43). The central response to these mediators is
bolstered by activation of microglia and astrocytes in the spinal cord, which are upregulated
following colitis (37,44). Astrocyte networks then may convey this signal from DRG at one level
to another (Figure 3). Understanding the interactions of the sensory neuron and glial cells in the
primary afferent pathway, and also the biochemical mediators involved in the signaling will be
very important in the path towards mitigating such referred pain.

1.6 TrkB.T1
TrkB.T1 is a truncated isoform of the TrkB receptor. This isoform is known to be
upregulated during fetal growth and becomes one of the common Trk receptor isoforms present
in adults (48). TrkB.T1 deficient mice were noted to be able to develop normally, but exhibited
anxious behaviors more often than control animals and had neuronal abnormalities in the
amygdala. Recent studies indicate that the TrkB.T1 receptor may actually have a maladaptive
role in response to disease or injury (49). Specifically, TrkB.T1 receptors are increased in SGCs
after peripheral inflammation, maintaining BDNF signaling. This receptor isoform has also been
found to induce astrocytic morphogenesis in response to BDNF, and astrocyte networks play a
key role in central sensitization post-inflammation (37). TrkB.T1 therefore carries potential as a
therapeutic target to treat neuropathic pain.
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1.7 Akt
Akt is a serine/threonine protein kinase involved in various cellular processes, primarily
to support cell survival/proliferation. Activity of Akt is regulated by post-translational
modifications, such as phosphorylation or ubiquitination. Phosphorylation of Akt by a kinase
leads to its activation, while dephosphorylation via a phosphatase can be a means of regulation.
Additionally, Akt is known to promote survival through inhibition of apoptotic processes and is
therefore implicated in various types of cancer (45). Akt can be activated by multiple factors
such as cytokines, growth factors and neurotrophins. Growing evidence shows that Akt also
participates in the processes of visceral hypersensitivity and somatic pain. For example, an Akt
inhibitor was able to block the NGF upregulation which occurred during gastric hypersensitivity
(46). TRPV1 upregulation, which was noted to occur with TNBS-induced colitis, involved the
PI3K/Akt pathway (34). TNBS-induced colitis models also have shown evidence of CGRP
triggering an increase in Akt phosphorylation, which leads to central sensitization and allows for
crosstalk between segments along the spinal cord (47).

1.8 Piezo2
The Piezo channel family has been evolutionarily conserved and play a vital role in the
mechanotransducive processes of different cell types (50). Piezo2, in particular, is known to be
involved in touch sensation, respiration and proprioception. Piezo2 deficient mice have been
noted as unable to sense discriminative touch (51). Piezo2 plays a role in sensory pathways and
has specifically been localized in sensory neurons of DRG and marks neurons that respond to
mechanical stimulation (52). It’s role in pain has become clearer with time, and the expression of
this channel has notably increased in nerve-injury induced mechanical pain (51). When
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considering visceral hypersensitivity, a former study showed that Piezo2 knockdown in the DRG
resulted in attenuation of visceral sensation to innocuous or noxious stimuli (53).

1.9 Summary
Previous studies indicate that TNBS-induced inflammation can lead to referred somatic
pain innervated by a DRG heterosegmental to the DRG innervating the colorectum. However,
the cellular mediators and mechanism(s) by which this can occur are understudied. The goal of
this study is to characterize the expression of p-Akt in L4 DRG following colitis induction and
the regulation of p-Akt by TrkB.T1-mediated cellular events in order to understand the molecular
pathways in viscerosomatic cross-sensitization.
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Objectives And Aims

Objectives
The objective of this study is to ascertain which signaling pathway may be involved in
the development of referred somatic pain resulting from viscerosomatic cross-sensitization.

Hypothesis
TNBS-induced inflammation leads to somatic hypersensitivity which is associated with
changes in neurochemical coding in L4 DRG and is regulated by BDNF/TrkB.T1.

Aims:
Aim 1: Establish behavior evidence of somatic hypersensitivity developing after induction of
visceral inflammation
Aim 2: Determine which group of afferent neurons (DRG) innervate the affected somatic region
Aim 3: Investigate the cellular mediator involved in the development of viscerosomatic crosssensitivity.
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Methods
Experimental Animals
Adult Black 6 male mice weighing 25-30 grams were used for all studies All
experimental protocols involving animal use were approved by the Institutional animal Care and
Use Committee at the Virginia Commonwealth University (IACUC# AM10315). Animal Care
was in accordance with the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) and National Institutes of health guidelines. All efforts were made to minimize
the potential for animal pain, stress, or distress as well as to reduce the number of animals used.

Introduction of Colonic Inflammation in Mice with TNBS
Under anesthesia (2.5 % isoflurane), a single dose of TNBS (75 µL of 12.5 µg/µL TNBS
in 30 % EtOH) was administered into the mouse colon via a polyethylene (PE)-50 catheter
through the anus. The proximal tip of the catheter was 2.5 cm inside from the anus. The mouse
tail was lifted for 1 min after TNBS installation to avoid drug leakage from the anus. The same
amount of 30 % EtOH as vehicle was used in control animals. TNBS-treated mice developed
peak colonic inflammation on day 3-4 and persistent visceral hypersensitivity after inflammation
resolution (> 7 days) [9,12,19].

Von Frey Test
The mice were placed individually into cages with a mesh floor underneath. They were
then allowed to acclimatize to their environment for 30 minutes. After this period, a
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microfilament was applied perpendicularly to the plantar surface of the hindpaw when the animal
has all four paws resting on the floor. The responses were recorded in a treatment blind manner,
with a response considered as positive if a withdrawal behavior (paw licking, shaking, or
withdrawal) was noted during or immediately after application. The mice were each
consecutively tested for a filament size, and this was repeated five times before moving on to a
filament size of higher force. These tests were conducted 1 week, 2 weeks and 3 weeks postinjection. More than one animal was used for each experimental group to show variability.

Perfusion and tissue dissection
Animals were put under anesthesia (2.5% isoflurane) in an induction chamber. The mouse was
then kept under anesthesia, and a lateral incision was made through the integument and
abdominal wall. A small incision was then made in the diaphragm along the entire length of the
rib cage to expose the pleural cavity. Tissue surrounding the heart was trimmed away, and
another incision was made to the animal’s right atrium. A needle was then secured into the
posterior end of the left ventricle, at which point the mouse was perfused with Krebs Buffer to
flush out blood. After the fluid became clear, the buffer valve was switched to administer the
fixative buffer, 4% paraformaldehyde (PFA). The valve was then closed once the fixative was
nearly finished and the mouse became stiff. Next, an incision was made to the back to expose the
spinal column, which was then isolated from the animal. Muscle, fat, and soft tissues were then
trimmed away from the column, and DRG were collected and stored in 4% PFA for 2 hours.
After 2 hours in 4% PFA, the tissues were transferred to sucrose for overnight.
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Fast Blue administration
Under anesthesia (2.5% isoflurane), mice were administered Fast Blue in the plantar
surface of their hindpaw to retrogradely label the primary afferents responsible for hindpaw
sensation. DRG tissues from T13, L1, L2, L3, L4, L5, L6, and S1 were collected 1 week postFast Blue administration, after which the mice went through whole-body perfusion as previously
mentioned. After dissection, the DRG were kept in 4% paraformaldehyde for 2 hours and then
stored in 20% sucrose overnight. Each DRG was then embedded in OCT cryostat medium
(Tissue Tek), sectioned at 10 µm thickness, and placed on gelatin coated slides for examination
in a microscope.

Immunohistochemistry
The DRG were taken out from 20% sucrose and embedded in OCT cryostat medium
(Tissue Tek). Each ganglion was then sectioned at 10 µm thickness and placed on gelatin-coated
slides. Slides were then heated at 35° for 15-30 minutes or until the sections were no longer
frozen. A hydrophobic border was then placed around the slide using a Pap Pen prior to
application of the primary antibody solution. Slides were then incubated overnight with specific
primary antibody at room temperature in 2% Normal Donkey Serum and 0.3% Triton Buffer.
Following incubation, slides were washed with a 0.1M sodium phosphate buffer at a pH of 7.4
for ten minutes three times. Slides were then incubated with a fluorescent species-specific
secondary antibody for two hours. The slides were then washed again with 0.1M sodium
phosphate buffer three times for ten minutes each. Citiflour anti-fadent mounting medium
(Electron microscopy Science) was then added onto the slides before placement of the cover
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slips. Slides were viewed with an Axiocam Carl Zeiss microscope and neurons exhibiting
immunoreactivity greater than the background level were considered positively stained.

Transgenic mice
Piezo2 reporter mice were generated by crossing Piezo2EGFP-IRES-Cre mice (Jax Stock
No. 027719) with R26-LSL-Gi-DREADD (Jax Stock No. 026219) so that Piezo2-expressing
cells can be visualized by mCitrine yellow fluorescent protein (YFP). TrkB.T1 global knockout
mice were obtained from NIH/NCI and a gift from Dr. Lino Tessarollo. All these transgenic
mice received TNBS treatment in parallel to wildtype mice.

Immunohistochemical Analysis
DRG cells exhibiting immunoreactivity greater than the observed background level were
considered positively stained. The number of positive cells in an area of the DRG were then
counted. The overall area was also measure excluding areas with no cells and/or with nerve
fibers. The area was converted from units of (µm^2) to units of (mm^2), and the cells per area
(mm^2) were then calculated.

Statistical Analysis
Results of each study were shown as the mean ± SEM. Multiple groups were compared
by ANOVA with differences between means considered significant at p£ 0.05. When two groups
were compared, a t test was used.
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Figure 4: Von Frey Test. TNBS-induced and control animals were placed in cages with a mesh
floor underneath a designated time post-injection. After a 30 minute acclimatization period, their
somatic sensitivity was tested by mechanical stimulation of a hindpaw with Von Frey filaments
of increasing size.
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Figure 5: Fast Blue Retrograde Tracing. Mice were administered Fast Blue, and DRG tissues
(T13, L1, L2, L3, L4, L5, L6, and S1) were removed from the mice 1 week post-injection.
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Figure 6: Immunohistochemistry Design. L4 DRG of control and TNBS-administered mice
were dissected 2 weeks post-injection. After collection of L4 DRG tissues,
immunohistochemistry was conducted for specific cellular mediators.
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Results
4.1 TNBS-induced mice develop somatic hypersensitivity which peaks 2 weeks post-TNBS
administration
1 week-post TNBS administration, TNBS treated mice began to exhibit a higher number
of withdrawal responses relative to control mice once filaments of 0.04-1.0 grams-force were
applied. 2 weeks-post TNBS administration, the treated mice exhibited a higher number of
withdrawal responses at 0.04-1.0 grams-force than the previous week, and still more than control
mice. 3 weeks-post administration the treated and control mice began to have a similar number
of withdrawal responses (Figure 7). These results were obtained from two animals per
experimental group.

4.2 Fast Blue Retrograde tracing revealed that sensory afferents innervating the hindpaws
are localized in L4 DRG
Tissue analysis was conducted 1 week post-Fast Blue administration to the hindpaw, and
DRG tissue (T13, L1, L2, L3, L4, L5, L6, and S1) dissection revealed evidence of fast blue
primarily in neurons of DRG at spinal levels L4, L5 and L6. Of those, L4 had a significantly
higher number of neuronal cells exhibiting presence of the fast blue dye (p<0.05). These results
were obtained from 4 paws of 2 animals (Figure 8).

4.3 The PI3K/Akt pathway is activated in TNBS-induced somatic hypersensitivity
Immunohistochemical studies were conducted to characterize the role of the PI3K/Akt
pathway in development of referred somatic pain. Analysis of images showed that TNBS-treated
mice exhibited significantly higher levels of p-Akt in L4 DRG than control mice (p<0.05). These
results were obtained using 6 animals per experimental group (Figure 9).
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4.4 Increased p-Akt co-expression in Piezo2 labeled cells in L4 DRG of TNBS-treated mice
P-Akt colocalization was analyzed in control and TNBS treated Piezo-YFP labeled
transgenic mice to investigate the involvement of Akt activation in mechanical sensitization.
Findings suggest that the TNBS treated transgenic mouse had greater p-Akt and Piezo
colocalization than the control transgenic animal. These results were obtained with one animal
per experimental group (Figures 10 and 11).

4.5 TrkB.T1 KO attenuates TNBS-induced increase in p-Akt levels in L4 DRG
In order to further distinguish the involvement of the PI3K/Akt pathway in crosssensitization further immunochemistry was conducted with control, TNBS, and TNBS +
TrkB.T1 KO mice. Immunohistochemical analysis revealed that p-Akt levels in the L4 DRG of
TrkB.T1 KO mice are significantly lower than those in the L4 DRG of TNBS treated mice
(p<0.05). These results were obtained with 6 animals for the control and TNBS treatment
groups, and 3 animals for the TrkB.T1 KO + TNBS treatment group (Figure 12).
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Figure 7: Von Frey Test for Mechanical Sensitivity. Graphs display the number of times out
of 5 that each mouse exhibited withdrawal response to stimulation for increasing filament sizes
(n=2 for both experimental groups) at A. 1 week post-TNBS or saline administration B. 2 weeks
post-TNBS or saline administration C. 3 weeks post-TNBS or saline administration
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Figure 8: Fast Blue Retrograde Tracing. A. Imaging of L4 DRG containing Fast Blue Dye,
red arrows point to cells positive for Fast Blue dye B. Imaging of sections from each DRG reveal
that sensory afferents innervating the hindpaw are primarily localized in L4 DRG (* p<0.05)
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Figure 9: Changes in p-Akt levels after TNBS-induced inflammation. A. Images of control
versus TNBS-treated DRG B. Enlarged image of TNBS treated L4 DRG with arrows pointing
to positively stained cells C. TNBS-treated mice have increased levels of p-Akt in L4 DRG
(n=6, * p<0.05)
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Figure 10: p-Akt expression in Piezo-YFP labeled DRG cells. A. Images showing sections
of control L4 DRG with Piezo-YFP (green), p-Akt (red), and their colocalization with arrows
pointing to positive cells B. Images showing sections of TNBS-treated L4 DRG with Piezo-YFP
(green), p-Akt (red), and their colocalization with arrows pointing to positive cells
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Figure 11: Percentage of Piezo2 cells expressing p-Akt. A. Enlarged images of merged
control and TNBS-treated L4 DRG, with arrows pointing to cells positive for p-Akt and Piezo
colocalization. B. Percentage of Piezo-YFP cells expressing p-Akt increases in TNBS-treated
L4 DRG (n=1).
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Figure 12: Effect of TrkB.T1 KO on p-Akt expression after TNBS induced inflammation.
A. Images of L4 DRG from control, TNBS treated, and TNBS + TrkB.T1 KO. B. The increase
in p-Akt levels in TNBS treated mice is attenuated by TrkB.T1 KO (Control and TNBS: n=6,
TrkB.T1 KO: n=3), * p<0.05 for TNBS vs control, ** p<0.05 for TNBS vs TNBS +TrkB.T1
KO.

38

TNBS

CONTROL

A.

TNBS + TrkB.T1 KO

p-Akt Protein Expression
250

*

200

B.

Cells/Area(mm^2)

**
150

100

50

0
Control

TNBS

TNBS+ TrkB.T1 KO

39

Discussion
Inflammatory Bowel Disease (IBD) is a chronic disease affecting millions of people
around the world and its prevalence continues to grow. A major contributor to a patient’s
discomfort is visceral hypersensitivity, which is also experienced by patients with Irritable
Bowel Syndrome (IBS). This hypersensitization is attributed to increased inflammatory
signaling from primary afferent neurons in the dorsal root ganglion (DRG), and various changes
in afferent signaling can lead to the persistence of sensitization. Additionally, a subset of patients
with IBD or IBS report development of referred somatic pain, such as neck pain or leg pain,
adding to their discomfort (54). The goal of this study is to investigate the underlying cellular
mediators which may facilitate the development of such viscerosomatic cross-sensitivity.
In this study, Von Frey tests exhibited that 2,4,6-trinitrobenzene sulfonic acid (TNBS)
treated mice began to show mechanical hypersensitivity after one week, and that hypersensitivity
peaked two weeks after TNBS administration. Of note, TNBS treated mice also exhibited
agitative behavior by attempting to ram their heads into the top of the cage two weeks postinjection, and this was not observed in the control mice. After three weeks, the behavior of the
treated mice in response to mechanical stimulation indicated attenuation of their hindpaw
hypersensitivity. Retrograde Fast Blue tracing showed that hindpaw innervation primarily takes
place through sensory afferents in the L4 dorsal root ganglion (DRG), and this is supported by
findings in a previous study (42).
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Immunohistochemistry conducted on L4 DRG revealed that phospho-Akt levels were
higher in TNBS-treated mice compared to the control, suggesting that the PI3K/Akt pathway is
involved in signaling from visceral afferent neurons to those innervating the hindpaw. Previous
studies show that an increase in Akt phosphorylation has been noted to occur in L6 DRG of mice
with TNBS-induced colitis and the activation of the PI3K/Akt pathway is believed to play a role
in spinal central sensitization (37). The increase of phospho-Akt in L4 DRG of TNBS-treated
mice noted in this study emphasizes the importance of the PI3K/Akt pathway in spinal cord
sensitization and heterosegmental cross-talk. Additionally, colocalization of phospho-Akt and
Piezo2 was noted to increase in TNBS-treated animals. Piezo2 is an important gated ion channel
expressed by a portion of sensory neurons and is vital for touch sensation. The expression of this
channel has been noted to increase in inflammatory conditions, and studies have shown Piezo2 to
be a mediator of mechanical sensitization (51). Therefore, the increased colocalization of Piezo2
and phospho-Akt in TNBS-treated mice further supports the role of the PI3K/Akt pathway in
referred somatic pain.
The increase in phospho-Akt levels in TNBS-treated mice was found to be partially
attenuated in TNBS-treated TrkB.T1 knockout mice. The TrkB.T1 receptor is a truncated form
of the TrkB receptor and has a high affinity for BDNF (37). This receptor is upregulated in
satellite glial cells (SGCs) during peripheral inflammation, ensuring response to BDNF
signaling. The attenuation of phospho-Akt levels in TNBS-treated TrkB.T1 knockout mice
indicates that glial cells (SGCs and astrocytes) play a role in somatic hypersensitization. Previous
studies examining induced cross-sensitization, specifically of the colon and bladder, have shown
that microglia and astrocytes are upregulated in response to inflammation (37,44). These cells
start to show high expression of BDNF receptors, and astrocytic TrkB.T1 receptors are known to
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induce morphogenesis upon activation. The BDNF increase in sensory neurons can release to the
spinal cord therefore inducing increased levels of astrocytes and microglia in the spinal cord, and
activation of TrkB.T1 receptors in these non-neuronal cells may allow for the transmission of
nociceptive signaling to a distinct DRG via Akt activation.
In conclusion, our findings show that the PI3K/Akt pathway plays a central role in
viscerosomatic cross-sensitization. Akt activation is noted to increase in Piezo2 labeled cells,
which may be a response indicative of the TNBS-induced somatic mechanical hypersensitivity.
BDNF upregulation due to visceral inflammation leads to central sensitization, and activation of
the PI3K/Akt pathway via TrkB.T1 receptors allows for the transmission of inflammatory signals
through the spinal cord to a heterosegmental DRG, leading to referred somatic pain.
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